Mocellin Simone, Rossi Carlo R, Brandes Alba, Nitti Donato
Surgery Branch, Department of Oncological and Surgical Sciences, University of Padova, Via Giustiniani 2, 35128 Padua, Italy.
Cancer Treat Rev. 2006 Feb;32(1):9-27. doi: 10.1016/j.ctrv.2005.10.003. Epub 2005 Dec 9.
The therapeutic approach to soft tissue sarcomas (STS) has evolved over the past two decades based on the results from randomized controlled trials, which are guiding physicians in the treatment decision-making process. Despite significant improvements in the control of local disease, a significant number of patients ultimately die of recurrent/metastatic disease following radical surgery due to a lack of effective adjuvant treatments. In addition, the characteristic chemoresistance of STS has compromised the therapeutic value of conventional antineoplastic agents in cases of unresectable advanced/metastatic disease. Therefore, novel therapeutic strategies are urgently needed to improve the prognosis of patients with STS. Recent advances in STS biology are paving the way to the development of molecularly targeted therapeutic strategies, the efficacy of which relies not only on the knowledge of the molecular mechanisms underlying cancer development/progression but also on the personalization of the therapeutic regimen according to the molecular features of individual tumours. In this work, we review the state-of-the-art of conventional treatments for STS and summarize the most promising findings in the development of molecularly targeted therapeutic approaches.
在过去二十年中，基于随机对照试验的结果，软组织肉瘤（STS）的治疗方法不断发展，这些试验为医生的治疗决策过程提供了指导。尽管在局部疾病控制方面取得了显著进展，但由于缺乏有效的辅助治疗，大量患者在根治性手术后最终死于复发/转移性疾病。此外，STS的特征性化疗耐药性降低了传统抗肿瘤药物在不可切除的晚期/转移性疾病中的治疗价值。因此，迫切需要新的治疗策略来改善STS患者的预后。STS生物学的最新进展为分子靶向治疗策略的发展铺平了道路，其疗效不仅依赖于对癌症发生/进展潜在分子机制的了解，还依赖于根据个体肿瘤的分子特征对治疗方案进行个性化定制。在这项工作中，我们回顾了STS传统治疗的最新进展，并总结了分子靶向治疗方法开发中最有前景的发现。
